Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Published Only

Predictors of Preferences for Use of MK-1293 Pens among Patients with Diabetes—Findings from a Multinational Study in the U.S., Canada, and U.K.

  1. BERHANU ALEMAYEHU,
  2. ALLISON M. NGUYEN,
  3. MARCO DIBONAVENTURA,
  4. BIJAL SHAH-MANEK,
  5. CHITRA KARKI and
  6. MICHAEL CRUTCHLOW
  1. Kenilworth, PA, North Wales, PA, New York, NY, Vallejo, CA, Boston, MA, Upper Gwynedd, PA
Diabetes 2018 Jul; 67(Supplement 1): -. https://doi.org/10.2337/db18-2272-PUB
Previous
  • Article
  • Figures & Tables
  • Info & Metrics
Loading

Abstract

This study examines the predictors of preferences of pen devices used with originator insulin glargine and MK-1293, a recently approved biosimilar insulin glargine (referred to as “Pen X”), among patients with diabetes. Adult patients with type 1/type 2 diabetes were recruited from commercial panels in the U.S., Canada, and the UK for one hour study visits. Respondents rated several attributes of each pen along with overall preferences for each of the two insulin pens. Non-inferiority analyses were conducted to compare ratings of the originator insulin glargine pen with Pen X. Logistic regression modeling was conducted to identify predictors of overall preference. A total of N=177 patients completed the study: mean age of 53.2 years, 56% males, with 73% type 2 diabetes. Overall, 63.2% preferred Pen X, 22.3% preferred originator insulin glargine pen and 14.5% had no preference. Except for employment, demographics were not significantly associated with overall preference, however the ease of pushing the injection button, instruction booklet and overall quality of the pen were predictive of an overall preference of Pen X (Table 1).The current study suggests that >60% of patients preferred Pen X and that overall, functional use and individual pen characteristics were the strongest predictors of preference, after adjusting for other pen characteristics.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Disclosure B. Alemayehu: Employee; Self; Merck & Co., Inc. A.M. Nguyen: Employee; Self; Merck & Co., Inc. M. DiBonaventura: Employee; Self; Pfizer Inc.. Consultant; Self; Merck & Co., Inc.. B. Shah-Manek: None. C. Karki: None. M. Crutchlow: Employee; Self; Merck & Co., Inc.. Consultant; Spouse/Partner; Novo Nordisk Inc., Zealand Pharma A/S, XOMA Corporation.

  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

Previous
Back to top
Diabetes: 67 (Supplement 1)

In this Issue

July 2018, 67(Supplement 1)
  • Table of Contents
  • Index by Author
  • Abstract PDFs
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predictors of Preferences for Use of MK-1293 Pens among Patients with Diabetes—Findings from a Multinational Study in the U.S., Canada, and U.K.
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Predictors of Preferences for Use of MK-1293 Pens among Patients with Diabetes—Findings from a Multinational Study in the U.S., Canada, and U.K.
BERHANU ALEMAYEHU, ALLISON M. NGUYEN, MARCO DIBONAVENTURA, BIJAL SHAH-MANEK, CHITRA KARKI, MICHAEL CRUTCHLOW
Diabetes Jul 2018, 67 (Supplement 1) 2272-PUB; DOI: 10.2337/db18-2272-PUB

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Predictors of Preferences for Use of MK-1293 Pens among Patients with Diabetes—Findings from a Multinational Study in the U.S., Canada, and U.K.
BERHANU ALEMAYEHU, ALLISON M. NGUYEN, MARCO DIBONAVENTURA, BIJAL SHAH-MANEK, CHITRA KARKI, MICHAEL CRUTCHLOW
Diabetes Jul 2018, 67 (Supplement 1) 2272-PUB; DOI: 10.2337/db18-2272-PUB
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Tables
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

Published Only

  • Gut Microbiota as a Potential Target for Treatment of Polycystic Ovary Syndrome
  • Betatrophin Is Associated with Type 2 Diabetes and Markers of Insulin Resistance
  • Relationship between NK Cell Activity and Glucose Regulation in Type 2 Diabetes Patients
Show more Published Only

Clinical Diabetes/Therapeutics

  • Patient Experience after Being Discharged with Newly Prescribed Insulin or Oral Hypoglycemic Agents
  • The Study on the Clinical Efficacy of Insulin Degludec/Insulin Aspart (IDegAsp)
Show more Clinical Diabetes/Therapeutics

Clinical Therapeutics/New Technology–Insulin Delivery Systems

  • A Reusable Cap for Disposable Insulin Pens Protects Insulin against Temperature-Induced Degradation
  • Long-Term Use of Omnipod® Insulin Management System Associated with Lower A1c in Adults with Established Diabetes and A1c =8%
Show more Clinical Therapeutics/New Technology–Insulin Delivery Systems

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.